Patient-reported quality of life (QOL) following CTL019 in pediatric and young adult patients (pts) with relapsed/refractory (r/r) b-cell acute lymphoblastic leukemia (B-ALL).
Andrew C. Dietz(Dana-Farber/Boston Children's Cancer and Blood Disorders Center), Andrew C. Harris(Primary Children's Hospital), Gary Douglas Myers(Baylor College of Medicine), Eneida R. Nemecek(Oregon Health & Science University), Jochen Buechner(Oslo University Hospital), Lawrence Rasouliyan, Heather E. Stefanski(National Marrow Donor Program), Barbara De Moerloose(Ghent University Hospital), Stephan A. Grupp(Children's Hospital of Philadelphia), Gregory A. Yanik(University of Michigan), Theodore W. Laetsch(Children's Hospital of Philadelphia), Henrique Bittencourt(Centre Hospitalier Universitaire Sainte-Justine), Yiyun Zhang, Paul L. Martin(Duke University), Sweta Shah(Novartis (United States)), Patricia A. Wood(Albany Stratton VA Medical Center Albany), Hidefumi Hiramatsu(Kyoto University), Simu K. Thomas, Françoise Méchinaud(Hotel Dieu Hospital)
Cited by 2
Related Papers
Tisagenlecleucel in Children and Young Adults with B-Cell Lymphoblastic Leukemia
|New England Journal of Medicine|2018|5.7k
ASTCT Consensus Grading for Cytokine Release Syndrome and Neurologic Toxicity Associated with Immune Effector Cells
|Transplantation and Cellular Therapy|2018|3.6k
The Molecular Basis of Turcot's Syndrome
|New England Journal of Medicine|1995|1.1k
Comprehensive Analysis of Hypermutation in Human Cancer
|Cell|2017|795